ATLASSupernus Pharmaceuticals (SUPN) earnings date: expected January 15–21
Supernus Pharmaceuticals (SUPN) has not announced its next earnings date yet. Based on its last 4 reports, ATLAS expects it around January 15–21. That is an estimate, not a confirmed date.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on SUPN
| Last price | $41.92 (+0.2%) |
|---|---|
| Normal 1-day range (±1σ) | ±2.1% |
| Earnings beat history | Beat the EPS estimate in 4 of the last 6 reports |
These figures come from the same calibrated model and valuation as the Supernus Pharmaceuticals stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Expected around January 15–21 (estimate). One email the day before, with ATLAS’s read on Supernus Pharmaceuticals. You can switch it off at any time.
Alert me before SUPN reportsFree to start. Creating an account takes under a minute.
SUPN earnings at a glance
| Next report | Not announced · expected around January 15–21 (ATLAS estimate) |
|---|---|
| Last report | Oct 29, 2026 · Beat |
| Beat rate (last 6 reports) | 4 of 6 (67%) |
| Average EPS surprise | +56.3% |
| Average move around a report | ±5.1% (last 5) |
| Sector | Healthcare · Drug Manufacturers - Specialty & Generic |
The expected window is an ATLAS estimate: it takes the typical gap between Supernus Pharmaceuticals’s last 4 reports and adds it to the most recent one. Companies announce the real date a few weeks ahead, and ATLAS switches the page to the confirmed date as soon as it is published.
Supernus Pharmaceuticals earnings history: last 6 reports
Supernus Pharmaceuticals last reported on Oct 29, 2026: EPS of $0.78 against an estimate of $0.34 (+129.4% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Oct 29, 2026 | $0.34 | $0.78 | +129.4% | Beat | – |
| Aug 3, 2026 | $0.51 | $0.53 | +3.9% | Beat | -3.1% |
| Jun 15, 2026 | $0.13 | $0.15 | +15.4% | Beat | -1.9% |
| May 14, 2026 | -$0.11 | -$0.11 | 0.0% | In line | -3.8% |
| May 5, 2026 | $0.28 | $0.21 | -25.0% | Miss | +5.8% |
| Feb 24, 2026 | $0.28 | $0.88 | +214.3% | Beat | +11.1% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for SUPN
See the fair value, the probability range and the earnings history of Supernus Pharmaceuticals on its ATLAS page.
Supernus Pharmaceuticals (SUPN) stock analysisPlans from €3.99 a month.
Supernus Pharmaceuticals earnings: frequently asked questions
When is Supernus Pharmaceuticals (SUPN) next earnings date?
Supernus Pharmaceuticals has not announced its next report. Its last 4 reports came Oct 29, 2026, Aug 3, 2026, May 14, 2026, Feb 24, 2026, so ATLAS estimates the next one around January 15–21. This is an estimate based on that pattern, not a confirmed date.
How often does SUPN beat earnings estimates?
Of its last 6 reports with a recorded result, Supernus Pharmaceuticals beat the EPS estimate 4 times; the average surprise was +56.3%. Past results do not predict the next one.
How much does SUPN move around earnings?
Over its last 5 reports the stock moved an average of 5.1% (absolute, from the close before the report day to the close after it), and finished higher 2 of 5 times.
Did Supernus Pharmaceuticals beat earnings estimates last quarter?
Supernus Pharmaceuticals last reported on Oct 29, 2026: EPS of $0.78 against an estimate of $0.34 (+129.4% surprise), a beat.
How much does SUPN usually move in a day?
On a normal trading day the ATLAS model puts SUPN’s one-day range at about ±2.1%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Educational information, not investment advice. Disclaimer